Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 14th July 2021
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Zoetis found in breach of NOAH medicines promotion code
NOAH has ruled that Zoetis UK Limited has breached its Code of Practice for the Promotion of Animal Medicines.

The case involved unsubstantiated claims about CircoMax® Myco. 

The National Office of Animal Health (NOAH) has ruled that Zoetis UK Limited has breached its Code of Practice for the Promotion of Animal Medicines.

NOAH’s Code of Practice on the Promotion of Animal Medicines Committee met in June 2021 to discuss a case brought about by Hipra UK and Ireland Ltd. The case involved promotional claims made between March and May 2021 for Zoetis’ product, CircoMax® Myco.

Hipra UK and Ireland Ltd complained that Zoetis had made unsubstantiated claims that CircoMax® Myco provides the broadest protection and broader coverage against porcine circovirus (PCV2).

Among these claims included the phrases: “Stay one step ahead with the broadest, longest-lasting combined PCV2 and M.hyo* protection” and “Protect your pigs with Europe’s first and only dual PCV2 genotype vaccine. Broader coverage – against multiple PCV2 genotype and Mycoplasma hyopneumoniae”.

A NOAH press release reads: ‘Following comprehensive presentations from both parties and detailed analysis of the scientific and technical background, the Committee found that in their promotional statements, Zoetis promoted its CircoMax® Myco vaccine as providing better and broader protection against the PCV2 virus than other vaccines on the market and that the evidence presented was not sufficient to substantiate such claims.'

Further details about the case are available on the NOAH website.

 

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.